Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Di-azetidinyl diamide as monoacylglcerol lipase inhibitors

a technology of diazetidinyl diamide and monoacylglcerol, which is applied in the direction of biocide, drug composition, animal repellent, etc., can solve the problem of difficult to separate the beneficial effects of these compounds from the unwanted side effects

Active Publication Date: 2013-08-01
JANSSEN PHARMA NV
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the use of synthetic cannabinoid agonists have conclusively demonstrated that increased cannabinoid signaling produces analgesic and anti-inflammatory effects, it has been difficult to separate these beneficial effects from the unwanted side effects of these compounds.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Di-azetidinyl diamide as monoacylglcerol lipase inhibitors
  • Di-azetidinyl diamide as monoacylglcerol lipase inhibitors
  • Di-azetidinyl diamide as monoacylglcerol lipase inhibitors

Examples

Experimental program
Comparison scheme
Effect test

example 5

[0216]

[0217]2-{1′-[(6-Phenylnaphthalen-2-yl)carbonyl]-1,3′-biazetidin-3-yl}-2,3-dihydro-1H-isoindol-1-one, Cpd 69

[0218]A mixture of compound 90 (40 mg, 0.08 mmol), phenylboronic acid (21 mg, 0.17 mmol), K2CO3 (23 mg, 0.17 mmol), and Pd(dppf)Cl2.CH2Cl2 (4 mg, 0.005 mmol) in EtOH (0.75 mL) and H2O (0.15 mL) was heated in a microwave reactor at 130° C. for 30 min. The mixture was diluted with CH2Cl2, washed with H2O, dried over Na2SO4 and concentrated. Purification by flash column chromatography (silica gel, 3% MeOH / CH2Cl2) gave compound 69 (34 mg). MS 474 (M+H+).

[0219]Following the procedure described above for Example 5 and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following compounds of the present invention were prepared:

CpdName and data2N-(1′-{[3′-(Trifluoromethyl)biphenyl-4-yl]carbonyl}-1,3′-biazetidin-3-yl)-1,3-thiazole-4-carboxamide.1H NMR (CHLOROFORM-d, 400 MHz): δ = 8.77 (s, 1H), 8.18 (d, J = 2.4 ...

example 6

[0220]

A. tent-Butyl 3-(benzyl(methyl)amino)azetidine-1-carboxylate, 6b

[0221]To a solution of 1-Boc-azetidin-3-one 1d (1.0 g, 5.85 mmol) and N-methyl-benzylamine 6a (1.02 g, 8.43 mmol) in 1,2-dichloroethane (12 mL) and acetic acid (1 mL) was added Na(OAc)3BH (1.30 g, 6.13 mmol). The reaction mixture was stirred at room temperature for 20 h. The reaction was quenched by the addition of aq. NaHCO3. The resulting mixture was extracted with CH2Cl2. The organic solution was dried over Na2SO4 and concentrated. Purification by flash column chromatography (silica gel, 40% EtOAc / heptane) gave compound 6b (1.40 g).

B. tent-Butyl 3-(benzyl(methyl)amino)-[1,3′-biazetidine]-1′-carboxylate, 6d

[0222]Intermediate 6d was prepared following the procedure described in Step B of Example 1.

C. (3-(Benzylmethyl)amino)-[1,3′-biazetidin]-1′-yl)(6-(trifluoromethyl)benzo[b]thiophen-2-yl)methanone, 6f

[0223]Intermediate 6f was prepared following the procedure described in Example 4.

D. N-Methyl-N-(1′-{[6-(trifluor...

examples 7-28

provide synthetic routes to useful intermediates for the preparation of compounds of Formula (I).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows:wherein Q and Z are defined herein.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]Not applicable.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT[0002]The research and development of the invention described below was not federally sponsored.BACKGROUND OF THE INVENTION[0003]Cannabis sativa has been used for the treatment of pain for many years. Δ9-tetrahydrocannabinol is a major active ingredient from Cannabis sativa and an agonist of cannabinoid receptors (Pertwee, Brit J Pharmacol, 2008, 153, 199-215). Two cannabinoid G protein-coupled receptors have been cloned, cannabinoid receptor type 1 (CB1 Matsuda et al., Nature, 1990, 346, 561-4) and cannabinoid receptor type 2 (CB2 Munro et al., Nature, 1993, 365, 61-5). CB1 is expressed centrally in brain areas, such as the hypothalamus and nucleus accumbens as well as peripherally in the liver, gastrointestinal tract, pancreas, adipose tissue, and skeletal muscle (Di Marzo et al., Curr Opin Lipidol, 2007, 18, 129-140). CB2 is predominantly expressed in immune ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/397A61K31/454A61K31/4035A61K31/429A61K31/423
CPCC07D205/04C07D403/14C07D409/14C07D413/14C07D417/12C07D417/14A61K31/454A61K31/397A61K31/4035A61K31/423A61K31/427A61K31/428A61K31/429C07D513/04A61P1/00A61P1/02A61P1/04A61P1/06A61P1/16A61P1/18A61P11/00A61P11/02A61P13/02A61P13/10A61P15/00A61P17/00A61P17/02A61P17/04A61P19/02A61P21/00A61P25/04A61P25/06A61P29/00A61P31/00A61P43/00
Inventor CONNOLLY, PETER J.MACIELAG, MARK J.ZHU, BIN
Owner JANSSEN PHARMA NV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com